Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Escitalopram for OCD
NCT00305500Phase 3Completed
- Sponsor
- Abarbanel Mental Health Center
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of escitalopram in obsessive compulsive disorder (OCD), sponsored by Abarbanel Mental Health Center. Primary endpoint: Safety as recorded by adverse-events and side-effects reports at 18 weeks. Started Mar 2006; status: completed.
02
Drugs
escitalopram
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00305500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305500.